Drug Trial Radar · NCT05822843
A Phase 1 Study of ESG206 in Adult Subjects With B-cell Lymphoid Malignancies
Last checked: Nov 19, 2026Latest source record: Sep 12, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
13
Actual
Start
Aug 2, 2023
Primary completion
Jan 22, 2025
Study completion Jan 22, 2025
Sponsor
- Lead sponsor
- Shanghai Escugen Biotechnology Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Apr 21, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase I, multicenter, open label, sequential-cohort, dose escalation study of ESG206. The purpose is to evaluate the clinical safety, tolerability, PK (pharmacokinetics), and preliminary efficacy and to establish the MTD (maximum tolerated dose), if any, and RP2D (recommended phaseII dose) of ESG206 in adult subjects with B lymphoid malignancies.
Conditions
- B-cell Lymphoid Malignancies
Interventions
ESG206Drug
Administered via intravenous (IV) infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants Experiencing Any Treatment Emergent Adverse EventsTime frame: First dose date up to last dose plus 30 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Beijing Cancer Hospital
Beijing, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.